ORKA Stock Analysis: Buy, Sell, or Hold?
ORKA - Oruka Therapeutics, Inc. Common Stock
$45.23
0.75 (1.69%)
▲
5d:
+8.83%
30d:
+31.44%
90d:
+42.68%
HOLD
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 13, 2026
Get Alerted When ORKA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: ORKA is 12.4% above fair value ($40.25). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: ORKA is 12.4% above fair value ($40.25). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: ORKA is currently trading at $45.23, which is considered extended relative to its 30-day fair value range of $32.34 to $40.25.
Technical Outlook: Technically, ORKA is in a strong uptrend. Immediate support is located at $37.55, while resistance sits at $47.25.
Market Sentiment: ORKA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $62.33 (+40.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ORKA is in a strong uptrend. Immediate support is located at $37.55, while resistance sits at $47.25.
Market Sentiment: ORKA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $62.33 (+40.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$32.34 -
$40.25
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BEARISH: Price significantly overextended (+12.4% above fair value)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 40.1% below Wall St target ($62.33)
Fair Price Analysis
30-Day Fair Range
$32.34 -
$40.25
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$37.55
Resistance Level
$47.25
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-17.66
Wall Street Target
$62.33
(+40.1%)
Share & Embed Analysis
Last updated: March 30, 2026 1:57 PM ET
Data refreshes hourly during market hours. Next update: 2:57 PM
Data refreshes hourly during market hours. Next update: 2:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ORKA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Arjun Agarwal
SELL
395 shares
2026-03-16
Joana Goncalves
SELL
7641 shares
2026-03-16
Lawrence Otto Klein
SELL
1729 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 62 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 48 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 57 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$109 | 45 HOLD |
